May 02, 2022 7:00am EDT Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Apr 05, 2022 7:00am EDT Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
Mar 28, 2022 7:00am EDT Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
Mar 14, 2022 7:00am EDT Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
Mar 11, 2022 7:00am EST Can-Fite’s Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv
Jan 31, 2022 7:00am EST Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
Jan 13, 2022 7:00am EST Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
Jan 10, 2022 7:26am EST Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
